Press Molding Operator

BD (Becton, Dickinson and Company) launched its Liverty TIPS Stent Graft in the US on October 28, 2026. The device treats portal hypertension, a liver condition that can cause internal bleeding or fluid buildup in the abdomen. The system is a transjugular intrahepatic portosystemic shunt (TIPS) device. It lets physicians tailor treatment to a patient's anatomy, disease progression, and clinical goals, and BD says it is the longest TIPS stent graft on the market. The launch follows use in Europe. It is backed by six-month interim results from the ARCH study, which enrolled 177 patients and is the first IDE study with clinical data on small TIPS diameters of 6-7mm.

Becton Dickinson has announced a major US manufacturing agreement ahead of its fiscal 2026 fourth quarter earnings report on November 5. A larger domestic footprint could support supply resilience and service levels, and help its push into recurring, higher value medtech platforms such as BioPharma Systems and BD COR. Analysts expect earnings to grow while sales fall. Consensus sees revenue declining 1.6% a year over three years, with profit margins rising from 7.3% to 15.6% by about 2029. Earnings are forecast to reach $3.3 billion by around September 2029, up from $1.6 billion today. Forecasts range from $2.4 billion to $4.6 billion. Key risks include product quality, regulatory issues, pressure in China, and slowing demand tied to Alaris remediation.

BD celebrates 65 years of manufacturing, innovation and community partnership in Canaan. Generations of Connecticut employees have helped ensure the reliable supply of the BD(R) Syringe, an essential medical device clinicians rely on every day in patient care around the world CANAAN, Conn., Oct. 6, 2026 /PRNewswire/ - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today marked 65 years of manufacturing in Canaan, Conn., the birthplace of the world's first fully sterile, single-use disposable plastic syringe and the largest syringe manufacturing operation in the United States. The site opened in 1961 with eight employees in a 25,000-square-foot building producing about 10 million syringes a year. The invention of the BD(R) Syringe helped enable the shift away from reusable glass syringes, reducing the risk of patient-to-patient disease transmission. Today, more than 500 employees work at the 385,000-square-foot facility, producing more than 2 billion syringes each year, supporting care from routine vaccinations to critical procedures. Over six decades, the Canaan team has supported major public health efforts, including smallpox eradication, H1N1 vaccination programs and the COVID-19 response. "The BD(R) Syringe was invented here in Canaan as a breakthrough in patient safety and has become an essential part of care around the world, touching 80 patients every second," said Eric Borin, worldwide president, Medication Delivery Solutions at BD. "For 65 years, generations of employees have continued to improve how we manufacture while delivering the quality and precision clinicians count on. This milestone is a testament to their dedication and the difference their work makes for patients every day." BD has invested more than $34 million in the Canaan site over the past five years to expand production capacity, modernize operations and support future growth. This includes three new syringe manufacturing lines and equipment upgrades that strengthen supply assurance. These investments reflect BD's commitment to U.S. manufacturing and to helping healthcare systems maintain reliable access to high-quality medical technologies. "Connecticut has a proud history of turning innovation into products that improve people's lives, and BD's Canaan facility is a powerful example," said Governor Ned Lamont. "For 65 years, this site has supported good jobs, strengthened our manufacturing economy and produced medical devices used in patient care around the world. BD's continued investment in Canaan demonstrates the strength of Connecticut's workforce and the important role our state plays in manufacturing essential healthcare products." A Connecticut legacy with global reach BD leaders, elected officials, employees and community partners gathered at the Canaan facility to celebrate its 65-year history and contributions to healthcare, manufacturing and the regional economy. That legacy is reflected in the generations of employees who have built careers at the site. More than 50 have at least 25 years of service, including 10 who have been with BD for 40 years or more. "BD has been an important part of northwestern Connecticut for 65 years, providing local jobs while manufacturing a product that supports patient care around the world," said State Representative Maria Horn and State Senator Stephen Harding in a joint statement. "The Canaan facility shows how advanced manufacturing can create meaningful opportunities in our communities while making a difference far beyond our state. We congratulate the employees who have made this milestone possible and welcome BD's continued investment in the region." As part of the celebration, BD will announce a $10,000 grant to the Community Health & Wellness Center, a Federally Qualified Health Center that provides accessible, high-quality healthcare to residents of northwestern Connecticut. The grant brings BD's support since 2024 to $90,000 helping fund nutrition programs, emergency assistance and transportation for patients in need. The partnership reflects BD's longstanding commitment to strengthening the communities where employees live and work. About BD BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health(TM) by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with Becton, Dickinson and Company on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson. | Contacts: | / | | Media | Investors | | Matt Marcus VP, Public Relations [email protected] | Shawn Bevec SVP, Investor Relations [email protected] | SOURCE BD (Becton, Dickinson and Company)